This data-based intelligencer will continue to be updated based on new financial documents so that readers can stay modern. Companies must submit with SEC or SEDAR and be modern to be considered for inclusion. When we started this resource in May 2019, quarterly-income companies, more than $ 2.5 million. As the industry has received a scale, since more companies have published, we later raised the minimum, including $ 12.5 million on September 2020. $ 50 million ($ 68.8 million), and the junior list now has at least $ 25 million ($ 34.4 million).
Note about regulated operating income
In May 2019 we added an additional meter, “adjusted operating income” We detailed In our news. The calculation takes the reported operating income and adjusts it for any change in the real value of biological assets required under IFRS accounting. We believe that this adjustment improves the comparison of companies in IFRS and NAS accounting. We note that frequently income can include one-time compensation, inventory writing or public listing costs, and we recommend that readers understand this unterior materials on quarterly finance. Many companies have been transferred from ITMS to NAS Account, which reduced our need to make adjustments. Please note that our ranking includes only actual reported income and not Pro Forma IncomeWe also note that companies with non-Cannabis actions should provide financial statements in the level of sector, which details not only income, but also operating profits, which must have their operating profits. Aurora Canepis is currently (TSX: ACB), Jazz Pharma (NASDAQ: JH) and TILRAY (TSX: TLRY) does not provide this information.
Tracker Inclusion Updates:
On July 27, at the time of our latest update, 16 companies are qualified for the inclusion of senior lists, including $ 13 and 3 in Canadian currency and 3 have had 13 companies. Currently, 13 companies presenting US dollars and 3 that file in Canadian dollars are the Senior lists, 16 in total. The younger list includes 11 companies that make 11 companies in Canadian dollars. The income of the public Cannabis and the income search engine now includes 29 companies. One company, farmland (NASDAQ. In Canada, both junior list names, canopy growth and organ have moved to a senior list.
Companies were reported to be reported in late July
Since our latest update, almost all Armenian companies have announced their June quarterly reports.
Senior and Junior – US Dollar Report
All recently reported all five MSOS, and the results were not particularly impressive. Curaleaf (OTC: Curlf) (TSX: Cura) has saved the income leader, which decreased by 8% a year ago. Thuelieve (OTC: TCNNF) (CSE: TRUL) saw the income unchanged a year ago. Green Thumb Industries (OTC: GTBIF) (CSE: GTII) has experienced an income that increased by 5% compared to the previous year, but operating profits were sharply dipped. Verano Holdings (OTC: VRNOF) (NEO: VRNO) MSOS was 4th place in MSOS, but its income fell a year ago. CRESCO LABS (OTC: CRLBF) (CSE: CL) had the largest biggest MSOS downfall.
Looking ago, all senior list companies reported, although there are several companies in the junior list that have not yet been submitted. Before mid-November, none of the 5 largest MSOs provided for their Q3 financial statements, but here are the current prospect by Learn:
Curaleaf (OTC: Curlf) (TSX: Cura) – Revenues will drop from 4% to 317.2 million dollars, $ 10%
Thuelieve (OTC: TCNNF) (CSE:
Green Thumb Industries (OTC: GTBII) (CSE: GTII) – Revenues are expected to increase by 1% by 291.0 million dollars, 82.3 million dollars
Verano Holdings (OTC: VRNOF) (Neo: VRNO) – Revenues will be reduced from 6% to $ 203.1 million, with an Ebitda, 6% to $ 60.6 million
Cresco Labs (OTC: CLBF) (CSE: CL) – Revenues will be reduced by 9% to $ 163.8 million adjusted eBitda, decreased by $ 36.7 million
Senior and Junior – Canadian Dollar Report
Nipple (NASDAQ: SNDL) (CSE: SNDL) is possible cannabis income and a year ago. Aurora hemp (NASDAQ. ACB) (TSX: ACB) The revenues seen again a year ago, but slipped successively. Canopy (NASDAQ. CGC) (TSX. Weed) had a great operational loss, although it was a decline a year ago. Organic global (NASDAQ. OGI) (TSX. OGI) has shown a large increase in revenue that stimulates achievements.
Currently, there are still calls for senior companies.
Cannabis Cannabis Revenue Tracker is not a proposal by New Cannabis Ventures, and you should not use it as investment advice. Tilde next to the date means an approximate date. All calculations come from sec or sedar files. For any question or licensing requests please Contact usA number
Based on the Houston, Alan cries out his experience as the founder of the online community 420 InvestorThe first and still the biggest decent diligent platform focused on the shares sold in the cannabis industry. Alan continues to find new ways to connect industry and facilitate its sustainable growth in the Canepuni community. Approximately New hemp enterprisesHe is responsible for content development and strategic alliances. Until the early 2013 focuses on the cannabis industry, Alan, who began his career in Wall Street, worked as more than two decades of research and portfolio. Article 650 of the Article 650 published in 2007 Looking for alphaWhere he has 70,000 followers, Alan is a frequent speaker for industry conferences and a Frequent source The media, including NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Ration | Facebook | Connection | Email
Statistics Canada has released February retail sales for the country, with Cannabis sales are declining from January levels, down 7.9% from the previous month to C$440.5 million. The sequential decrease increased by 2.0% on a daily basis due to fewer days than in the previous month. January, originally reported at C$466.1 million, was revised higher to C$478.2 million. February sales rose 7.9% from a year ago, down 9.4% from last month, and 8.3% in May and 7.5% in June, but better than last year’s slowest growth rate since legalization -0.9% in September 2024 due to the BC strike. Total sales are expected to increase by 4.5% to C$5.39 billion in 2024 and by 4.1% to C$5.62 billion in 2025. So far in 2026, sales are up 8.6%.
An increase in the number of shops, as well as a fall in the prices of flowers that attract consumers from the illegal market, have boosted sales. In Ontario, the most populous province, sales fell 11.4% from January and 3% from a year ago. Alberta was down 10.2% from January, but up 1% from a year ago. British Columbia was up 3.7% from January and up 33% from a year ago, while Quebec was down 9.6% from January but up 30% from a year ago.
March sales data will be released on May 22.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
Aurora Cannabis accelerates global medical cannabis leadership with proactive acquisition of Safari Flower, expanding EU GMP capabilities to serve growing high-margin international markets.
EDMONTON, AB, April 15, 2026. /PRNewswire/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company based in Canada, is pleased to announce that it has acquired Safari Flower, an EU GMP certified cannabis developer and manufacturer. The aggregate consideration is valued at $26.5 million, subject to customary adjustments and including a $2 million cash payment contingent on the satisfaction of certain conditions (the “Deal”).
“The acquisition of Safari Flower is an important milestone for Aurora as we continue to make targeted investments in expanding our EU GMP capabilities to support the rapidly growing international medical cannabis market. The expanded supply chain will enable us to capture greater international market share while delivering superior quality and value to our most valued patients around the world,” said Miguel Martin, Aurora’s Executive Chairman and Chief Executive Officer.
Strategic rationale
Safari Flower Company’s 59,000-square-foot, purpose-built EU GMP certified in-house processing and manufacturing facility in Ontario, Canada will provide the company with increased capacity that closely aligns with its existing cultivation and manufacturing facilities.
The increased capacity will be used to supply EU GMP flower to Aurora’s key international markets, including Germany, Australia, Poland and the UK, and will support further market expansion.
This transaction is expected to result in a positive adjusted EBITDA contribution in fiscal year 2027, with additional benefits in fiscal year 2028 and beyond as these assets are optimized in the Company’s supply chain.
Aurora intends to leverage its plant science and operational expertise to drive operational efficiencies, improve crop yields and support high-margin commercialization in international markets.
Transaction details
Aurora, through a wholly-owned subsidiary, has indirectly purchased 100% of the shares of 9869247 Canada Limited (“Safari Flower Company”) for an aggregate consideration of $26.5 million, including a cash payment of $2 million subject to the satisfaction of certain conditions. As closing consideration, Aurora (i) issued to the selling stockholder 2,417,180 shares of common stock; and (ii) paid the selling stockholder $15 million in cash, subject to customary post-closing adjustments.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves both medical and consumer markets in Canada, Europe, Australia and New Zealand with a strategic focus on high margin opportunities and a medical first approach. Aurora’s portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty’s® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products to open up the world to cannabis.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora common stock trades on the NASDAQ and TSX exchanges under the symbol “ACB”.
New Cannabis Ventures’ NCV Newswire aims to gather high-quality content and information about leading cannabis companies to help our readers filter through the noise and stay on top of the most important cannabis business news. The NCV Newswire is edited by an editor and is not automated in any way. Got a secret news tip? Get in touch.
You are reading this week’s edition of New Cannabis Ventures, a weekly magazine we have published since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve, as well as links to the most important news of the week. We no longer email them like we used to, but post this and all newsletters on our website here.
friends,
Just before Christmas, this newsletter discussed how Vireo Growth is getting pretty big. At the end of January I profiled how Vireo Growth is expanding its business. This week’s newsletters include six articles we’ve run since April 2, and Vireo Growth is central to two of them. Vireo Growth is big and getting bigger, but few people seem to care.
I’m not writing this to tell readers to care. In fact, while I used to include the company on my Focus List at 420 Investor, I no longer do. Earlier this month I wrote an article for my subscribers about why I keep looking at things but not including stocks in my Focus List. Here is the summary.
I watch VREOF because it is now one of the largest MSOs by revenue, but it continues to fall short of joining the Global Hemp Stock Index due to its low trading volumes. Average daily trading volume over the past month was 251,000 shares, which is about $100,000 in daily trading value. This is well below peers. Perhaps more importantly, the current price of $0.45, which is down 26.6% year-to-date, is significantly lower than the price of $0.625 for the last large cap in 2024. Not only are the investors not winning, but VREOF hsa distributed a lot of shares to the sellers and they are also under water.
Maybe Vireo Growth shares will reward their owners, or maybe it will continue to do so. I think hemp stock investors and debt holders should be asking why no one is thinking of this yet. Scotts Miracle-Gro, which has been public since 1992 and has a market cap of $3.6 billion, picked up much of VREOF’s stock when it spun off Hawthorne. The 213 million shares are “at an implied price of $0.60” per share, although VREOF hasn’t traded at $0.60 since January. When the divestiture was announced in late January, Vireo Growth closed at $0.5553.
So a large MSO that has reshuffled its management, is now in multiple markets, and has executed its plan to get bigger with several acquisitions, is still not responding to the cannabis investment community. I wish them the best.
Sincerely,
Alan:
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is what we have published in the last 2 weeks.
Follow Alan for real-time updates X.com:. Share and discover industry news with like-minded people on the largest group of cannabis investors and entrepreneurs LinkedIn:.
Stay on top of the most important communications from public companies by watching what’s coming cannabis investor calendar.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
